<a href="https://www.fiercebiotech.com/biotech/aacr-endeavoring-go-global-zai-lab-offers-reality-check-chinas-biotech-ascent" hreflang="en">AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent</a>
Zai Lab, a Chinese biopharma company, is striving to expand globally by leveraging its presence in both China and the U.S., while acknowledging the challenges posed by U.S. drug prices and regulatory expertise. Despite China's growing biotech capabilities, Zai Lab's leadership emphasizes that significant innovations in drug development are still likely to emerge from the U.S. and Europe.
Zai Lab's strategy to become a global biopharma highlights the importance of maintaining a U.S. presence due to higher drug prices and market potential, which are crucial for biopharmas with global aspirations. The company’s focus on leveraging strong relationships with Chinese trial sites for rapid early-stage trials, combined with its expansion into Western markets, presents an actionable model for other biotechs aiming to bridge Eastern and Western pharmaceutical landscapes. This approach underscores the value in diversifying geographic market strategies and capitalizing on regional strengths in clinical development.